Prestige Consumer Healthcare FY27 Q1 GAAP diluted EPS drops to $0.61; revenue rises 6.5% to $265.7 million

The company raised its fiscal 2027 outlook to include acquisitions, targeting revenue of USD 1.29 billion to USD 1.32 billion; adjusted diluted EPS is seen at USD 4.55 to USD 4.65.

Prestige Consumer Healthcare posted fiscal 2027 Q1 net income of USD 29.2 million, down from USD 47.5 million a year earlier; diluted EPS fell to USD 0.61.

Revenue rose 6.5% year over year to USD 265.7 million, helped by gastrointestinal and dermatological strength; Breathe Right added USD 5.9 million.

GAAP operating income slid to USD 52.5 million from USD 71.8 million; interest expense, net climbed to USD 13.9 million from USD 10.2 million.

Adjusted diluted EPS increased to USD 0.98 from USD 0.95, reflecting non-GAAP add-backs tied mainly to acquisition-related costs.